Eucrisa (Crisaborole) Patent Expiration, LOE Window & CMS Spending

Eucrisa (Crisaborole) by Anacor: FDA Orange Book core substance LOE 2029-12-29 (last listed 2030-07-20), 1 AB generics, $77.0M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAnacor
FDA Application & PathwayN207695 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE Date2029-12-29
Last Listed Patent or Exclusivity Date2030-07-20
Orange Book Patents (*PED Extensions)8 patents (4 *PED)
Active AB-Rated Generic Competitors1
2024 CMS Total Public Spend$77.0M
2024 Medicare Part D Spend$9.3M
2024 Medicaid Spend$67.8M
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 14.7% 2-yr change)